Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gross Profit | $65.3M | $103.6M | $142.6M | $188.7M | $251.4M | $324.5M | $530.4M | $654.3M | $796.8M | $985.9M | $1,162.6M | $1,396.7M | $1,526.1M | $1,619.6M | $1,429.1M | $1,331.2M | $1,375.2M | $1,563.0M | $1,789.6M | $2,070.0M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, United Therapeutics Corporation's last 12-month Gross Profit is $2,451.4M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, United Therapeutics Corporation's Gross Profit growth was 25.0%. The average annual Gross Profit growth rates for United Therapeutics Corporation have been 20.6% over the past three years, 11.9% over the past five years.